Literature DB >> 16820137

Pulmonary and serum antibody responses elicited in zebu cattle experimentally infected with Mycoplasma mycoides subsp. mycoides SC by contact exposure.

Mamadou Niang1, Mahamadou Diallo, Ousmane Cisse, Mamadou Kone, Modibo Doucoure, James A Roth, Valérie Balcer-Rodrigues, Laurence Dedieu.   

Abstract

The purpose of the present study was to characterize the Mycoplasma mycoides subsp. mycoides small colony (MmmSC)-specific humoral immune response at both systemic and local levels in cattle experimentally infected with MmmSC, for a better understanding of the protective immune mechanisms against the disease. The disease was experimentally reproduced in zebu cattle by contact. Clinical signs, postmortem and microbiological findings were used to evaluate the degree of infection. Serum and bronchial lavage fluids (BAL) were collected sequentially, before contact and over a period of one year after contact. The kinetics of the different antibody isotypes to MmmSC was established. Based on the severity of the clinical signs, post mortem and microbiological findings, the animals were classified into three groups as acute form with deaths, sub-acute to chronic form and resistant animals. Seroconversion was never observed for the control animals throughout the duration of the experiment, nor for those classified as resistant. Instead, seroconversion was measured for all other cattle either with acute or sub-acute to chronic forms of the disease. For these animals, IgM, IgG1, IgG2 and IgA responses were detected in the serum and BAL samples. The kinetics of the IgM, IgG1 and IgG2 responses was nearly similar between both groups of animals. No evident correlation could thus be established between the levels of these isotypes and the severity of the disease. Levels of IgA were high in both BAL and serum samples of animals with sub-acute to chronic forms of the disease, and tended to persist throughout the entire experimental period. In contrast, animals with acute forms of the disease showed low levels of IgA in their BAL samples with none or very transient but low levels of IgA in the serum samples. Our results thus demonstrated that IgA is produced locally in MmmSC experimentally infected cattle by contact and may play a role in protection against contagious bovine pleuropneumonia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820137     DOI: 10.1051/vetres:2006032

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  13 in total

1.  Seroprevalence of contagious bovine pleuropneumonia (CBPP) in Mali.

Authors:  Amadou Séry; Cheick Abou Kounta Sidibé; Ousmane Cissé; Mamadou Diallo; Mamadou Koné; Agnès Waret-Szkuta; François Roger; François Thiaucourt; Mamadou Niang
Journal:  Trop Anim Health Prod       Date:  2014-11-30       Impact factor: 1.559

2.  Assessing the effectiveness of intubation as a challenge model in contagious bovine pleuropneumonia vaccine experiments.

Authors:  Isabel Gacheri Nkando; Hezron O Wesonga; Joseph K N Kuria; Declan McKeever
Journal:  Trop Anim Health Prod       Date:  2010-06-20       Impact factor: 1.559

3.  Performance evaluation of two serological tests for contagious bovine pleuropneumonia (CBPP) detection in an enzootic area using a Bayesian framework.

Authors:  Cheick Abou Kounta Sidibé; Vladimir Grosbois; François Thiaucourt; Mamadou Niang; Matthieu Lesnoff; François Roger
Journal:  Trop Anim Health Prod       Date:  2012-04-12       Impact factor: 1.559

4.  Assessment of the control measures for category A diseases of Animal Health Law: Contagious Bovine Pleuropneumonia.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Hans Spoolder; Karl Ståhl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Jan Arend Stegeman; François Thiaucourt; Sotiria-Eleni Antoniou; Inma Aznar; Alexandra Papanikolaou; Gabriele Zancanaro; Helen Clare Roberts
Journal:  EFSA J       Date:  2022-01-21

5.  Sero-positivity and associated risk factors for contagious bovine pleuropneumonia under two cattle production systems in North Central Nigeria.

Authors:  Nma Bida Alhaji; Olutayo Olajide Babalobi
Journal:  Trop Anim Health Prod       Date:  2015-11-12       Impact factor: 1.559

6.  Plasma levels of TNF-α, IFN-γ, IL-4 and IL-10 during a course of experimental contagious bovine pleuropneumonia.

Authors:  Flavio Sacchini; Mirella Luciani; Romolo Salini; Massimo Scacchia; Attilio Pini; Rossella Lelli; Jan Naessens; Jane Poole; Joerg Jores
Journal:  BMC Vet Res       Date:  2012-04-25       Impact factor: 2.741

7.  Serological testing of cattle experimentally infected with Mycoplasma mycoides subsp. mycoides Small Colony using four different tests reveals a variety of seroconversion patterns.

Authors:  Evelyn Schubert; Konrad Sachse; Jörg Jores; Martin Heller
Journal:  BMC Vet Res       Date:  2011-11-18       Impact factor: 2.741

8.  Whole Blood Transcriptome Analysis of Mycoplasma mycoides Subsp. mycoides-Infected Cattle Confirms Immunosuppression but Does Not Reflect Local Inflammation.

Authors:  Valérie Rodrigues; Philippe Holzmuller; Carinne Puech; Hezron Wesonga; François Thiaucourt; Lucía Manso-Silván
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

9.  Identification of genes coding for B cell antigens of Mycoplasma mycoides subsp. mycoides Small Colony (MmmSC) by using phage display.

Authors:  Dubravka R Miltiadou; Arshad Mather; Edy M Vilei; Dion H Du Plessis
Journal:  BMC Microbiol       Date:  2009-10-09       Impact factor: 3.605

10.  Cattle immunized against the pathogenic L-α-glycerol-3-phosphate oxidase of Mycoplasma mycoides subs. mycoides fail to generate neutralizing antibodies and succumb to disease on challenge.

Authors:  Musa M Mulongo; Joachim Frey; Ken Smith; Christian Schnier; Hezron Wesonga; Jan Naessens; Declan McKeever
Journal:  Vaccine       Date:  2013-09-11       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.